Chronic Rhinosinusitis

Chronic Rhinosinusitis is a prevalent inflammatory disease of the sinus that affects about 16% of the U.S. population. Patients experience significant declines in quality of life and daily productivity, leading to depression, migraines, cognitive deficits, and sleep dysfunction. The annual U.S. health care expenditure to treat patients is $64 billion underscoring the unmet need for new effective therapeutics. GlycoMira’s synthetic glycosaminoglycan technology represents a safe and effective alternative to existing therapies. Please contact us for more information.

Oral Mucositis

Oral mucositis is a seriously painful condition that many cancer patients experience during chemoradiation therapy. Patients experience agonizing pain in the mouth, making it difficult to eat and drink. Treatment options for oral mucositis are extremely limited. GlycoMira is developing therapeutics to treat this adverse effects in cancer patients. Our technology provides countermeasures to prevent inflammation in healthy tissues caused by chemoradiation. Please contact us for more information.


  • LL-37 causes cell death of human nasal epithelial cells, which is inhibited with a synthetic glycosaminoglycan (2017). More info.
  • Prevention of sinonasal inflammation by a synthetic glycosaminoglycan (2016). More info.
  • A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis (2016). More info.
  • Prevention of Anti-microbial Peptide LL-37-Induced Apoptosis and ATP Release in the Urinary Bladder by a Modified Glycosaminoglycan (2013) More info.
  • Physiologic Relevance of LL-37 Induced Bladder Inflammation and Mast Cells (2013). More info.
  • Novel Sulfated Polysaccharides Disrupt Cathelicidins, Inhibit RAGE and Reduce Cutaneous Inflammation in a Mouse Model of Rosacea (2011). More info
  • Low-Anticoagulant Heparins in the Treatment of Metastasis, Research on Melanoma – A Glimpse into Current Directions and Future Trends (2011). More info.
  • A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides (2011). More info.